Skip to main content

Table 1 Demographics. Demographics for all patients enrolled

From: Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine

  Treatment Arm  
1 (n = 9) 2 (n = 9) Overall
Age (years)    
 Median (range) 75 (67–82) 72 (66–85) 74 (66–85)
Race (n, %)    
 White / Caucasian 9 (100%) 9 (100%) 18 (100%)
ECOG Performance Status (n, %)    
 0 9 (100%) 8 (89%) 17 (94%)
 1 0 (0%) 1 (11%) 1 (6%)
Gleason score (n, %)    
  < 7 1 (11%) 2 (22%) 3 (17%)
 7 3 (33%) 4 (44%) 7 (39%)
 8 0 (0%) 2 (22%) 2 (11%)
  ≥ 9 5 (56%) 0 (0%) 5 (28%)
 Unknown 0 (0%) 1 (11%) 1 (6%)
Metastatic sites (n, %)    
 Visceral 2 (22%) 0 (0%) 2 (11%)
 Bone 2 (22%) 5 (56%) 7 (39%)
 Distant lymph nodes 6 (67%) 4 (44%) 10 (56%)
Baseline PSA (ng/mL)    
 Median (range) 32.6 (4.17–1090) 11.2 (2.09–68.4) 16.25 (2.09–1090),
Baseline PSA doubling time (months)    
 Median (range) 2.8 (1.4–63.9) 2.2 (1.0–25.8) 2.55 (1.0–63.)